Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Nicolaas H. Prins"'
Autor:
Joachim Grevel, Garrit Jentsch, Rupert Austin, Nicolaas H. Prins, John Lettieri, David Mitchell, Funan Huang, Marcia S. Brose, Martin Schlumberger, Gerold Meinhardt, Carol E. A. Peña, Bart A. Ploeger
Publikováno v:
Clinical and Translational Science, Vol 12, Iss 5, Pp 459-469 (2019)
Sorafenib is an oral multikinase inhibitor approved for the treatment of differentiated thyroid carcinoma (DTC), renal cell carcinoma, and hepatocellular carcinoma. In the phase III DECISION trial in patients with DTC, sorafenib exposure and the inci
Externí odkaz:
https://doaj.org/article/f459c9a764c849519f2e779c790d916b
Autor:
John Lettieri, Funan Huang, Rupert P. Austin, Martin Schlumberger, Marcia S. Brose, Nicolaas H. Prins, Carol Peña, Gerold Meinhardt, David Mitchell, Garrit Jentsch, Bart Ploeger, Joachim Grevel
Publikováno v:
Clinical and Translational Science
Clinical and Translational Science, Vol 12, Iss 5, Pp 459-469 (2019)
Clinical and Translational Science, Vol 12, Iss 5, Pp 459-469 (2019)
Sorafenib is an oral multikinase inhibitor approved for the treatment of differentiated thyroid carcinoma (DTC), renal cell carcinoma, and hepatocellular carcinoma. In the phase III DECISION trial in patients with DTC, sorafenib exposure and the inci
Publikováno v:
British Journal of Pharmacology. 143:331-342
This study aimed to determine, quantify and explain regional differences in the relaxant response to the selective 5-HT1 and 5-HT7 receptor agonist 5-carboxamidotryptamine (5-CT) throughout the canine stomach. Longitudinal muscle strips from eight ga
Publikováno v:
British Journal of Pharmacology. 120:714-720
1. Although conscious dogs have often been used for colonic motility studies with 5-hydroxytryptamine (5-HT), the effects of 5-HT on the isolated colon have not been thoroughly characterized yet. The current study was undertaken to characterize the r
Publikováno v:
Therapeutic Drug Monitoring, 28(2), 206-211. LIPPINCOTT WILLIAMS & WILKINS
Pharmacokinetic (PK) studies of oxaliplatin, using a dose regimen of 85 mg/m, are lacking. A PK model may be used in future studies to investigate the relationship between pharmacokinetics and dose limiting toxicity. The purpose of this study was to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::09a7118559794378cf0df3a4cb72d9b7
https://research.rug.nl/en/publications/8a424f79-b936-4c78-98f5-c806776693e1
https://research.rug.nl/en/publications/8a424f79-b936-4c78-98f5-c806776693e1
Publikováno v:
The Journal of pharmacology and experimental therapeutics. 317(3)
Quantification of different levels of 5-hydroxytryptamine4 (5-HT4) receptor agonism expression across animal species as well as across organs within the same animal species offers substantial potential for the separation of desired gastrointestinal v
Publikováno v:
American journal of physiology. Gastrointestinal and liver physiology. 289(1)
We aimed to evaluate the gastric relaxant capacity of the 5-HT1/7-receptor agonist 5-carboxamidotryptamine (5-CT) in conscious dogs and to clarify the mechanism of action by use of selective antagonists, vagotomy, and in vitro experiments. A barostat
Publikováno v:
Gastroenterology. 120:A753
Publikováno v:
Gastroenterology. 118:A847